Full-Time
Posted on 10/1/2025
Wearable defibrillator for sudden cardiac arrest
No salary listed
No H1B Sponsorship
Houston, TX, USA
In Person
| , |
Element Science creates medical devices to prevent sudden cardiac arrest. Its flagship product, Jewel, is a wearable external defibrillator intended to provide around-the-clock protection by monitoring the heart and delivering a life-saving shock when needed. Jewel is not yet commercially available in the U.S. This device works by continuously monitoring cardiac rhythm and, if a dangerous rhythm is detected, delivering a controlled electrical defibrillation; it is designed for use by at-risk individuals under medical guidance. The company differentiates itself by focusing on a wearable, user-friendly defibrillator and by prioritizing workforce diversity, equity, inclusion, and belonging (DEIB), as well as growth through team expansion. Element Science aims to bring Jewel to market, work with healthcare providers and insurers, increase accessibility for patients at risk of sudden cardiac arrest, and grow its market share while reducing deaths from cardiac events.
Company Size
51-200
Company Stage
Series C
Total Funding
$183.1M
Headquarters
San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Stock Options
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
FSA (Flexible Spending Accounts)
HSA (Health Savings Account)
Employee Assistance Program through PEO
Element Science, a San Francisco-based health technology company, has been named to Fast Company's World's Most Innovative Companies of 2026 list. The company developed the Jewel Patch Wearable Cardioverter Defibrillator, which monitors and protects cardiovascular patients from sudden cardiac arrest. The Jewel Patch-WCD received FDA approval in April 2025 and European CE mark certification in January 2024. The device is water-resistant, discreet and requires no daily maintenance, distinguishing it as the only wearable cardioverter defibrillator that can be worn whilst showering. The product is currently in early commercial launch across select US states, targeting over 500,000 patients in the US and Europe at temporary risk of sudden cardiac arrest. Element Science's investors include Third Rock Ventures, Google Ventures and Deerfield Management.
Element Science, an innovative health technology company pioneering a digital wearable platform that monitors and protects high-risk cardiovascular patients, announces that its Jewel(R) Wearable Patch Cardioverter Defibrillator (Jewel) has received the prestigious Red Dot Design Award.
With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company developing a pioneering digital wearable platform for high-risk cardiovascular patients, announced the appointment of Lee Smith Jr. as the company's first Head of Commercial
Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the BSI Group.The Jewel P-WCD was designed to address limitations with traditional garment-based WCDs. While these garment-based WCDs have demonstrated the ability to treat sudden cardiac arrest (SCA), a leading cause of death in the United States and in Europe, challenges related to patient comfort and compliance have resulted in avoidable deaths and limited their widespread adoption.The effectiveness of the Jewel defibrillator was confirmed in the Jewel EP Lab Study, conducted in Prague, Czech Republic, in which 16 patients experiencing ventricular arrhythmias were successfully converted to a normal heart rhythm after a single therapeutic shock. The Jewel IDE Study, a pivotal study of 305 patients presented at the American Heart Association’s 2023 Annual Scientific Sessions demonstrated significant patient compliance and protected time resulting in a high number of successful patient saves and no deaths or serious adverse events related to the device (www.ElementScience.com/ide-study/ ).Dr. Uday N
SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced that Trish Howell has been appointed as the Company’s new Chief Operating Officer, effective October 17, 2022. “ Ms. Howell is a transformational leader who has excelled in her positions prior to joining Element Science. As an innovative and seasoned executive, she expands the capabilities of our leadership team at an inflection point of our growth. Her experience in building successful commercial operations at medical device companies gives her a critically valuable perspective that will be an indispensable asset as we look forward to commercializing our technology and expanding our pipeline of products,” said Uday N. Kumar, MD, Founder, President and CEO